MX 2 is a novel regulator of cell cycle in melanoma cells

MX2 protein is a dynamin‐like GTPase2 that has recently been identified as an interferon‐induced restriction factor of HIV‐1 and other primate lentiviruses. A single nucleotide polymorphism (SNP), rs45430, in an intron of the MX2 gene, was previously reported as a novel melanoma susceptibility locus in genome‐wide association studies. Functionally, however, it is still unclear whether and how MX2 contributes to melanoma susceptibility and tumorigenesis. Here, we show that MX2 is differentially expressed in melanoma tumors and cell lines, with most metastatic cell lines showing lower MX2 expression than primary melanoma cell lines and melanocytes. Furthermore, high expression of MX2 RNA in primary melanoma tumors is associated with better patient survival. Overexpression of MX2 reduces in vivo proliferation partially through inhibition of AKT activation, suggesting that it can act as a tumor suppressor in melanoma. However, we have also identified a subset of melanoma cell lines with high endogenous MX2 expression where downregulation of MX2 leads to reduced proliferation. In these cells, MX2 downregulation interfered with DNA replication and cell cycle processes. Collectively, our data for the first time show that MX2 is functionally involved in the regulation of melanoma proliferation but that its function is context‐dependent

A survey of the clinicopathological and molecular characteristics of patients with suspected Lynch syndrome in Latin America

Background: Genetic counselling and testing for Lynch syndrome (LS) have recently been introduced in several Latin America countries. We aimed to characterize the clinical, molecular and mismatch repair (MMR) variants spectrum of patients with suspected LS in Latin America. Methods: Eleven LS hereditary cancer registries and 34 published LS databases were used to identify unrelated families that fulfilled the Amsterdam II (AMSII) criteria and/or the Bethesda guidelines or suggestive of a dominant colorectal (CRC) inheritance syndrome. Results: We performed a thorough investigation of 15 countries and identified 6 countries where germline genetic testing for LS is available and 3 countries where tumor testing is used in the LS diagnosis. The spectrum of pathogenic MMR variants included MLH1 up to 54%, MSH2 up to 43%, MSH6 up to 10%, PMS2 up to 3% and EPCAM up to 0.8%. The Latin America MMR spectrum is broad with a total of 220 different variants which 80% were private and 20% were recurrent. Frequent regions included exons 11 of MLH1 (15%), exon 3 and 7 of MSH2 (17 and 15%, respectively), exon 4 of MSH6 (65%), exons 11 and 13 of PMS2 (31% and 23%, respectively). Sixteen international founder variants in MLH1, MSH2 and MSH6 were identified and 41 (19%) variants have not previously been reported, thus representing novel genetic variants in the MMR genes. The AMSII criteria was the most used clinical criteria to identify pathogenic MMR carriers although microsatellite instability, immunohistochemistry and family history are still the primary methods in several countries where no genetic testing for LS is available yet. Conclusion: The Latin America LS pathogenic MMR variants spectrum included new variants, frequently altered genetic regions and potential founder effects, emphasizing the relevance implementing Lynch syndrome genetic testing and counseling in all of Latin America countries.Radium Hospital Foundation (Oslo, Norway) in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript, Helse Sør-Øst (Norway) in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript, the French Association Recherche contre le Cancer (ARC) in the analysis, and interpretation of data, the Groupement des Entreprises Françaises dans la Lutte contre le Cancer (Gefluc) in the analysis, and interpretation of data, the Association Nationale de la Recherche et de la Technologie (ANRT, CIFRE PhD fellowship to H.T.) in the analysis, and interpretation of data and by the OpenHealth Institute in the analysis, and interpretation of data. Barretos Cancer Hospital received financial support by FINEP-CT-INFRA (02/2010)info:eu-repo/semantics/publishedVersio

Quantitative Proteomic Analysis Reveals Metabolic Alterations, Calcium Dysregulation, And Increased Expression Of Extracellular Matrix Proteins In Laminin α2 Chain-deficient Muscle

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)Congenital muscular dystrophy with laminin α2 chain deficiency (MDC1A) is one of the most severe forms of muscular disease and is characterized by severe muscle weakness and delayed motor milestones. The genetic basis of MDC1A is well known, yet the secondary mechanisms ultimately leading to muscle degeneration and subsequent connective tissue infiltration are not fully understood. In order to obtain new insights into the molecular mechanisms underlying MDC1A, we performed a comparative proteomic analysis of affected muscles (diaphragm and gastrocnemius) from laminin α2 chain-deficient dy3K/dy3K mice, using multidimensional protein identification technology combined with tandem mass tags. Out of the approximately 700 identified proteins, 113 and 101 proteins, respectively, were differentially expressed in the diseased gastrocnemius and diaphragm muscles compared with normal muscles. A large portion of these proteins are involved in different metabolic processes, bind calcium, or are expressed in the extracellular matrix. Our findings suggest that metabolic alterations and calcium dysregulation could be novel mechanisms that underlie MDC1A and might be targets that should be explored for therapy. Also, detailed knowledge of the composition of fibrotic tissue, rich in extracellular matrix proteins, in laminin α2 chain-deficient muscle might help in the design of future anti-fibrotic treatments. All MS data have been deposited in the ProteomeXchange with identifier PXD000978 (http://proteomecentral.proteomexchange. org/dataset/PXD000978).131130013013Coordenação de Aperfeiçoamento de Pessoal de Nível Superior; 2014-10-6; CAPES; Coordenação de Aperfeiçoamento de Pessoal de Nível Superior; KAW2007.0118; Coordenação de Aperfeiçoamento de Pessoal de Nível SuperiorCoordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)Allamand, V., Guicheney, P., Merosin-deficient muscular dystrophy, autosomal recessive (mdc1a, mim#156225, lama2 gene coding for -2 chain of laminin) (2002) Eur. J. Hum. Genet., 10, pp. 91-94Helbling-Leclerc, A., Zhang, X., Topaloglu, H., Cruaud, C., Tesson, F., Weissenbach, J., Tomé, F.M.S., Guicheney, P., Mutations in the laminin -2 chain gene (lama2) cause merosin-deficient muscular dystrophy (1995) Nat. Genet., 11, pp. 216-218Voit, T., Tomé, F.S., The congenital muscular dystrophies (2004) Myology, 2, pp. 1203-1238. , (Angel, A., and Franzini-Armstrong, C., eds McGraw-Hill, New YorkIbraghimov-Beskrovnaya, O., Ervasti, J.M., Leveille, C.J., Slaughter, C.A., Sernett, S.W., Campbell, K.P., Primary structure of dystrophin-Associated glycoproteins linking dystrophin to the extracellular matrix (1992) Nature, 355, pp. 696-702Talts, J.F., Andac, Z., Gohring, W., Brancaccio, A., Timpl, R., Binding of the g domains of laminin -1 and -2 chains and perlecan to heparin, sulfatides, -dystroglycan and several extracellular matrix proteins (1999) EMBO J., 18, pp. 863-870Von Der Mark, H., Williams, I., Wendler, O., Sorokin, L., Von Der Mark, K., Pöschl, E., Alternative splice variants of -7-1 integrin selectively recognize different laminin isoforms (2002) J. Biol. Chem., 277, pp. 6012-6016Gawlik, K.I., Durbeej, M., Skeletal muscle laminin and mdc1a: Pathogenesis and treatment strategies (2011) Skelet. Muscle, 1, p. 9Han, R., Kanagawa, M., Yoshida-Moriguchi, T., Rader, E.P., Ng, R.A., Michele, D.E., Muirhead, D.E., Campbell, K.P., Basal lamina strengthens cell membrane integrity via the laminin g domain-binding motif of -dystroglycan (2009) Proc. Natl. Acad. Sci. U.S.A., 106, pp. 12573-12579Vachon, P.H., Xu, H., Liu, L., Loechel, F., Hayashi, Y., Arahata, K., Reed, J.C., Engvall, E., Integrins (-7-1) in muscle function and survival. Disrupted expression in merosin-deficient congenital muscular dystrophy (1997) J. Clin. Invest., 10, pp. 1870-1881Mayer, U., Integrins: Redundant or important players in skeletal muscle and beyond (2003) J. Biol. Chem., 279, pp. 14587-14590Gawlik, K.I., Mayer, U., Blomberg, K., Sonnenberg, A., Ekblom, P., Durbeej, M., Laminin -1 chain mediated reduction of laminin -2 chain deficient muscular dystrophy involves integrin -7-1 and dystroglycan (2006) FEBS Lett., 580, pp. 1759-1765Moll, J., Barzaghi, P., Lin, S., Bezakova, G., Lochmuller, H., Engvall, E., Muller, U., Ruegg, M.A., An agrin minigene rescues dystrophic symptoms in a mouse model for congenital muscular dystrophy (2001) Nature, 413, pp. 302-307Doran, P., Martin, G., Dowling, P., Jockusch, H., Ohlendieck, K., Proteome analysis of the dystrophin-deficient mdx diaphragm reveals a drastic increase in the heat shock protein cvhsp (2006) Proteomics, 6, pp. 4610-4621Gardan-Salmon, D., Dixon, J.M., Lonergan, S.M., Selsby, J.T., Proteomic assessment of the acute phase of dystrophin deficiency in mdx mice (2011) Eur. J. Appl. Physiol., 111, pp. 2763-2773Carberry, S., Zweyer, M., Swandulla, D., Ohlendieck, K., Proteomics reveals drastic increase of extracellular matrix proteins collagen and dermatopontin in the aged mdx diaphragm model of duchenne muscular dystrophy (2012) Int. J. Mol. Med., 30, pp. 229-234Ge, Y., Molloy, M.P., Chamberlain, J.S., Andrews, P.C., Proteomic analysis of mdx skeletal muscle: Great reduction of adenylate kinase 1 expression and enzymatic activity (2003) Proteomics, 3, pp. 1895-1903Guevel, L., Lavoie, J.R., Perez-Iratxeta, C., Rouger, K., Dubreil, L., Feron, M., Talon, S., Megeney, L.A., Quantitative proteomic analysis of dystrophic dog muscle (2010) J. Proteome Res., 10, pp. 2465-2449Matsumura, C.Y., Menezes De Oliveira, B., Durbeej, M., Marques, M.J., Isobaric tagging-based quantification for proteomic analysis: A comparative study of spared and affected muscles from mdx mice at the early phase of dystrophy (2013) PLoS One, 8, p. e65831Rayavarapu, S., Coley, W., Cakir, E., Jahnke, V., Takeda, S., Aoki, Y., Grodish-Dressman, H., Nagaraju, K., Identification of disease specific pathways using in vivo silac proteomics in dystrophin deficient mdx mouse (2013) Mol. Cell. Proteomics, 12, pp. 1061-1073Lewis, C., Carverry, S., Ohlendieck, K., Proteomic profiling of x-linked muscular dystrophy (2009) J. Muscle Res. Cell. Motil., 30, pp. 267-279De La Torre, C., Illa, I., Faulkner, G., Soria, L., Robles-Cedeno, R., Pereles-Dominguez-Perles, R., De Luna, N., Gallardo, E., Proteomics identification of differentially expressed proteins in the muscle of dysferlin myopathy patients (2009) Proteomics Clin. Appl., 3, pp. 486-497De Morrée, A., Hensbergen, P.J., Van Haagen, H.H., Dragan, I., Deelder, A.M., T'Hoen, P.A., Frants, R., Van Den Maarel, S.M., Proteomic analysis of the dysferlin protein complex unveils its importance for sarcolemmal maintenance and integrity (2010) PLoS One, 5, p. e13854Washburn, M., Wolters, D., Yates, J., III, Large scale analysis of the yeast proteome by multidimensional protein identification technology (2001) Nat. Biotechnol., 19, pp. 242-247Thompson, A., Schäfer, J., Kuhn, K., Kienle, S., Schwarz, J., Schmidt, G., Neumann, T., Hamon, C., Tandem mass tags: A novel quantification strategy for comparative analysis of complex protein mixtures by ms/ms (2003) Anal. Chem., 75, pp. 1895-1904Carmignac, V., Quere, R., Durbeej, M., Proteasome inhibition improves the muscle of laminin -2 chain-deficient mice (2011) Hum. Mol. Genet., 20, pp. 541-552Vizcaíno, J.A., Deutsch, E.W., Wang, R., Csordas, A., Reisinger, F., Ríos, D., Dianes, J.A., Hermjakob, H., Proteome-xchange provides globally co-ordinated proteomics data submission and dissemination (2014) Nat. Biotechnol., 32, pp. 223-226Karp, N.A., McCormick, P.S., Russell, M.R., Lilley, K.S., Experimental and statistical considerations to avoid false conclusions in proteomics studies using differential in-gel electrophoresis (2007) Mol. Cell. Proteomics, 6, pp. 1354-1364Storey, J.D., Tibshirani, R., Statistical significance for genome wide studies (2003) Proc. Natl. Acad. Sci. U.S.A., 100, pp. 9440-9445Levin, Y., The role of statistical power analysis in quantitative proteomics (2011) Proteomics, 11, pp. 2565-2567Gawlik, K., Miyagoe-Suzuki, Y., Ekblom, P., Takeda, S., Durbeej, M., Laminin -1 chain reduces muscular dystrophy in laminin -2 chain deficient mice (2004) Hum. Mol. Genet., 13, pp. 1775-1784Kline, K.G., Wu, C.C., Mudpit analysis: Application to human heart tissue (2009) Methods Mol. Biol., 528, pp. 281-293Martins De Souza, D., Oliveira, B.M., Castro-Dias, E., Winck, F.V., Horiuchi, R.S., Baldasso, P.A., Caetano, H.T., Novello, J.C., The untiring search for the most complete proteome representation: Reviewing the methods (2008) Brief Funct. Genomic. Proteomic., 7, pp. 312-321Miyagoe, Y., Hanaoka, K., Nonaka, I., Hayasaka, M., Nabeshima, Y., Arahata, K., Nabeshima, Y., Takeda, S., Laminin -2 chain-null mutant mice by targeted disruption of the lama2 gene: A new model of merosin (laminin 2)-deficient congenital muscular dystrophy (1997) FEBS Lett., 415, pp. 33-39Häger, M., Bigotti, M.G., Meszaros, R., Carmignac, V., Holmberg, J., Allamand, V., Åkerlund, M., Durbeej, M., Cib2 binds integrin -7b-1d and is reduced in laminin -2 chain-deficient muscular dystrophy (2008) J. Biol. Chem., 283, pp. 24760-247695Deconinck, N., Dan, B., Pathophysiology of duchenne muscular dystrophy: Current hypotheses (2007) Pediatr. Neurol., 26, pp. 1-7Vandebrouck, C., Martin, D., Colson-Van Schoor, M., Debaix, H., Gailly, P., Involvement of trpc in the abnormal calcium influx observed in dystrophic (mdx) mouse skeletal muscle fibers (2002) J. Cell Biol., 158, pp. 1089-1096Millay, D.P., Sargent, M.A., Osinska, H., Baines, C.P., Barton, E.R., Vuagniaux, G., Sweeney, H.L., Molkentin, J.D., Genetic and pharmacologic inhibition of mitochondrial-dependent necrosis attenuates muscular dystrophy (2008) Nat. Med., 14, pp. 442-447Millay, D.P., Goonasekera, S.A., Sargent, M.A., Maillet, M., Aronow, B.J., Molkentin, J.D., Calcium influx is sufficient to induce muscular dystrophy through a trpc-dependent mechanism (2009) Proc. Natl. Acad. Sci. U.S.A., 106, pp. 19023-19028Culligan, K.G., Ohlendieck, K., Abnormal calcium handling in muscular dystrophy (2002) Basic Appl. Myol., 12, pp. 147-157Straub, V., Rafael, J.A., Chamberlain, J.S., Campbell, K.P., Animal models for muscular dystrophy show different patterns of sarcolemmal disruption (1997) J. Cell Biol., 139, pp. 375-385Gawlik, K.I., Åkerlund, M., Carmignac, V., Elamaa, H., Durbeej, M., Distinct roles for laminin globular domains in laminin -1 chain mediated rescue of murine laminin -2 chain deficiency (2010) PLoS One, 5, p. e11549Rescher, U., Gereke, V., Annexins-unique membrane binding proteins with diverse functions (2004) J. Cell Sci., 117, pp. 2631-2639Probst-Cousinm, S., Berghoff, C., Neundörfer, B., Heuss, D., Annexin expression in inflammatory myopathies (2004) Muscle Nerve, 30, pp. 102-110Jeudi, S., Wardrop, K.E., Alessi, A., Dominov, J.A., Bcl-2 inhibits the innate immune response during early pathogenesis of murine congenital muscular dystrophy (2011) PLoS One, 6, p. e22369Taniguchi, M., Kurahashi, H., Noguchi, S., Sese, J., Okinaga, T., Tsukahara, T., Guicheney, P., Toda, T., Expression profiling from fukuyama-type congenital muscular dystrophy and laminin-2 deficient congenital muscular dystrophyIs congenital muscular dystrophy a primary fibrotic disease? (2006) Biochem. Biophys. Res. Commun., 342, pp. 489-502Kuang, W., Xu, H., Vachon, P.H., Engvall, E., Merosin-deficient congenital muscular dystrophy. Partial genetic correction in two mouse models (1998) J. Clin. Invest., 102, pp. 844-852Meinen, S., Barzaghi, P., Lin, S., Lochmuller, H., Rüegg, M.A., Linker molecules between laminins and dystroglycan ameliorate laminin-2-deficient muscular dystrophy at all disease stages (2007) J. Cell Biol., 176, pp. 979-993Doe, J.A., Wuebbles, R.D., Allred, E.T., Rooney, J.E., Elorza, M., Burkin, D.J., Transgenic overexpression of the -7 integrin reduces muscle pathology and improves viability in the dy(w) mouse model of merosin-deficient congenital muscular dystrophy type 1a (2011) J. Cell Sci., 124, pp. 2287-2297Girgenrath, M., Dominov, J.A., Kostek, C.A., Miller, J.B., Inhibition of apoptosis improves outcome in a model of congenital muscular dystrophy (2004) J. Clin. Invest., 114, pp. 1635-1639Erb, M., Meinen, S., Barzaghi, P., Sumanovski, L.T., Courdier-Fruh, I., Rüegg, M.A., Meier, T., Omigapil ameliorates the pathology of muscle dystrophy caused by laminin-2 deficiency (2009) J. Pharmacol. Exp. Ther., 331, pp. 787-795Kumar, A., Yamauchi, J., Girgenrath, T., Girgenrath, M., Musclespecific expression of insulin-like growth factor 1 improves outcome in lama2dy-w mice, a model for congenital muscular dystrophy type 1a (2011) Hum. Mol. Genet., 20, pp. 2333-2343Carmignac, V., Svensson, M., Körner, Z., Elowsson, L., Matsumura, C., Gawlik, K., Allamand, V., Durbeej, M., Autophagy is increased in laminin -2 chain-deficient muscle and inhibition improves muscle morphology in a mouse model of mdc1a (2011) Hum. Mol. Genet., 20, pp. 4891-4902Rooney, J.E., Knapp, J.R., Hodges, B.L., Wuebbles, R.D., Burkin, D.J., Laminin-111 protein therapy reduces muscle pathology and improves viability of a mouse model of merosin-deficient congenital muscular dystrophy (2011) Am. J. Pathol., 180, pp. 1593-1602Elbaz, M., Yanay, N., Aga-Mizrachi, S., Brunschwig, Z., Kassis, I., Ettinger, K., Barak, V., Nevo, Y., Losartan, a therapeutic candidate in congenital muscular dystrophy: Studies in the dy2j/dy2j mouse (2012) Ann. Neurol., 71, pp. 699-708Meinen, S., Lin, S., Rüegg, M.A., Angiotensin ii type 1 receptor antagonists alleviate muscle pathology in the mouse model for laminin-2-deficient congenital muscular dystrophy (mdc1a) (2012) Skelet. Muscle, 2, p. 18Turk, R., Sterrenburg, E., Van Der Wees, C.G., De Meijer, E.J., De Menezes, R.X., Groh, S., Campbell, K.P., Hoen, T.P.A., Common pathological mechanisms in mouse models for muscular dystrophies (2006) FASEB J., 20, pp. 127-129Chen, Y.W., Zhao, P., Borup, R., Hoffman, E.P., Expression profiling in the muscular dystrophies: Identification of novel aspects of molecular pathophysiology (2000) J. Cell Biol., 151, pp. 1321-1336Chinet, A.E., Even, P.C., Decrouy, A., Dystrophin-dependent efficiency of metabolic pathways in mouse skeletal muscles (1994) Experientia, 59, pp. 602-605Even, P.C., Decrouy, A., Chinet, A., Defective regulation of energy metabolism in the mdx-mouse skeletal muscles (1994) Biochem. J., 304, pp. 649-654Groh, S., Zong, H., Goddeeris, M.M., Lebakken, C.S., Venzke, D., Pessin, J.E., Campbell, K.P., Sarcoglycan complex: Implications for metabolic defects in muscular dystrophies (2009) J. Biol. Chem., 284, pp. 19178-19182Onopiuk, M., Brutkowski, W., Wierzbicka, K., Wojciechowska, S., Szczepanowska, J., Fronk, J., Lochmuller, H., Zablocki, K., (2009) Biochem. Biophys. Res. Commun., 386, pp. 463-466Le Borgne, F., Guyot, S., Logerot, M., Beney, L., Gervais, P., Demarquoy, J., Exploration of lipid metabolism in relation with plasma membrane properties of duchenne muscular dystrophy cells: Influence of l-carnitine (2012) PLoS One, 7, p. e49346Matsumura, C.Y., Pertille, A., Albuquerge, T.C., Santo Neto, H., Marques, M.J., Diltiazem and verapamil protect dystrophin-deficient muscle fibers of mdx mice from degeneration: A potential role in calcium buffering and sarcolemmal stability (2009) Muscle Nerve, 39, pp. 167-176Jørgensen, L.H., Blain, A., Greally, E., Lavala, S.H., Blamire, A.M., Davison, B.J., Brinkmeier, H., Lochmüller, H., Long-term blocking of calcium channels in mdx mice results in differential effects on heart and skeletal muscle (2011) Am. J. Pathol., 178, pp. 273-283Goonasekera, S.A., Lam, C.K., Millay, D.P., Sargent, M.A., Hajjar, R.J., Kranias, E.G., Molkentin, J.D., Mitigation of muscular dystrophy in mice by serca overexpression in skeletal muscle (2011) J. Clin. Invest., 121, pp. 1044-1052Horiuchi, K., Amizuka, N., Takeshita, S., Takamatsu, H., Katsuura, M., Ozawa, H., Toyama, Y., Kudo, A., Identification and characterization of a novel protein, periostin, with restricted expression to periosteum and periodontal ligament and increased expression by transforming growth factor (1999) J. Bone Miner. Res., 14, pp. 1239-1249Lorts, A., Schwanekamp, J.A., Baudino, T.A., McNally, E.M., Molkentin, J.D., Deletion of periostin reduces muscular dystrophy and fibrosis in mice by modulating the transforming growth factor- pathway (2012) Proc. Natl. Acad. Sci. U.S.A., 109, pp. 10978-10983Ting, L., Rad, R., Gygi, S.P., Haas, W., Ms3 eliminates ratio distortion in isobaric multiplexed quantitative proteomics (2011) Nat. Methods, 8, pp. 937-940Christoforou, A., Lilley, K.S., Taming the isobaric tagging elephant in the rooms in quantitative proteomics (2011) Nat. Methods, 8, pp. 911-91

ALPL-1 is a target for chimeric antigen receptor therapy in osteosarcoma

Osteosarcoma (OS) remains a dismal malignancy in children and young adults, with poor outcome for metastatic and recurrent disease. Immunotherapies in OS are not as promising as in some other cancer types due to intra-tumor heterogeneity and considerable off-target expression of the potentially targetable proteins. Here we show that chimeric antigen receptor (CAR) T cells could successfully target an isoform of alkaline phosphatase, ALPL-1, which is highly and specifically expressed in primary and metastatic OS. The target recognition element of the second-generation CAR construct is based on two antibodies, previously shown to react against OS. T cells transduced with these CAR constructs mediate efficient and effective cytotoxicity against ALPL-positive cells in in vitro settings and in state-of-the-art in vivo orthotopic models of primary and metastatic OS, without unexpected toxicities against hematopoietic stem cells or healthy tissues. In summary, CAR-T cells targeting ALPL-1 show efficiency and specificity in treating OS in preclinical models, paving the path for clinical translation

MX 2 is a novel regulator of cell cycle in melanoma cells

MX2 protein is a dynamin-like GTPase2 that has recently been identified as an interferon-induced restriction factor of HIV-1 and other primate lentiviruses. A single nucleotide polymorphism (SNP), rs45430, in an intron of the MX2 gene, was previously reported as a novel melanoma susceptibility locus in genome-wide association studies. Functionally, however, it is still unclear whether and how MX2 contributes to melanoma susceptibility and tumorigenesis. Here, we show that MX2 is differentially expressed in melanoma tumors and cell lines, with most metastatic cell lines showing lower MX2 expression than primary melanoma cell lines and melanocytes. Furthermore, high expression of MX2 RNA in primary melanoma tumors is associated with better patient survival. Overexpression of MX2 reduces in vivo proliferation partially through inhibition of AKT activation, suggesting that it can act as a tumor suppressor in melanoma. However, we have also identified a subset of melanoma cell lines with high endogenous MX2 expression where downregulation of MX2 leads to reduced proliferation. In these cells, MX2 downregulation interfered with DNA replication and cell cycle processes. Collectively, our data for the first time show that MX2 is functionally involved in the regulation of melanoma proliferation but that its function is context-dependent.status: publishe

ALPL-1 is a target for chimeric antigen receptor therapy in osteosarcoma

Abstract Osteosarcoma (OS) remains a dismal malignancy in children and young adults, with poor outcome for metastatic and recurrent disease. Immunotherapies in OS are not as promising as in some other cancer types due to intra-tumor heterogeneity and considerable off-target expression of the potentially targetable proteins. Here we show that chimeric antigen receptor (CAR) T cells could successfully target an isoform of alkaline phosphatase, ALPL-1, which is highly and specifically expressed in primary and metastatic OS. The target recognition element of the second-generation CAR construct is based on two antibodies, previously shown to react against OS. T cells transduced with these CAR constructs mediate efficient and effective cytotoxicity against ALPL-positive cells in in vitro settings and in state-of-the-art in vivo orthotopic models of primary and metastatic OS, without unexpected toxicities against hematopoietic stem cells or healthy tissues. In summary, CAR-T cells targeting ALPL-1 show efficiency and specificity in treating OS in preclinical models, paving the path for clinical translation

From colorectal cancer pattern to the characterization of individuals at risk: Picture for genetic research in Latin America

Colorectal cancer (CRC) is one of the most common cancers in Latin America and the Caribbean, with the highest rates reported for Uruguay, Brazil and Argentina. We provide a global snapshot of the CRC patterns, how screening is performed, and compared/contrasted to the genetic profile of Lynch syndrome (LS) in the region. From the literature, we find that only nine (20%) of the Latin America and the Caribbean countries have developed guidelines for early detection of CRC, and also with a low adherence. We describe a genetic profile of LS, including a total of 2,685 suspected families, where confirmed LS ranged from 8% in Uruguay and Argentina to 60% in Peru. Among confirmed LS, path_MLH1 variants were most commonly identified in Peru (82%), Mexico (80%), Chile (60%), and path_MSH2/EPCAM variants were most frequently identified in Colombia (80%) and Argentina (47%). Path_MSH6 and path_PMS2 variants were less common, but they showed important presence in Brazil (15%) and Chile (10%), respectively. Important differences exist at identifying LS families in Latin American countries, where the spectrum of path_MLH1 and path_MSH2 variants are those most frequently identified. Our findings have an impact on the evaluation of the patients and their relatives at risk for LS, derived from the gene affected. Although the awareness of hereditary cancer and genetic testing has improved in the last decade, it is remains deficient, with 39%–80% of the families not being identified for LS among those who actually met both the clinical criteria for LS and showed MMR deficiency